Abstract：
UNASSIGNED: This study aimed to evaluate trends in polypharmacy prevalence among adults with asthma in the United States.
UNASSIGNED: Data from the 2001-2020 National Health and Nutrition Examination Survey were used to estimate the weighted prevalence of polypharmacy. Joinpoint regression analysis was conducted to evaluate trends in polypharmacy. Trends were first evaluated overall and then stratified by asthma severity and asthma control. A multivariable logistic regression model was used to identify factors associated with polypharmacy.
UNASSIGNED: From 2001 to 2020, a stable trend in polypharmacy among U.S. adults with asthma was observed (average annual percent change [AAPC]=1.02, p=0.71). Trends across different asthma severity were stable (mild asthma: AAPC=2.93, p=0.20; moderate asthma: AAPC=-2.22, p=0.35; severe asthma: AAPC=0.45, p=0.82). Trends in adults with good asthma control and those with poor control stayed constant (good control: AAPC=0.82, p=0.68; poor control: AAPC=-1.22, p=0.82). Several factors, including older age, females, Non-Hispanic Black, health insurance coverage, family income, number of healthcare visits, former smokers, multi-morbidities, asthma severity, and asthma control, were associated with polypharmacy.
UNASSIGNED: Polypharmacy prevalence has remained constant among U.S. adults with asthma over the past two decades. Despite a stable overall trend, disparities in polypharmacy prevalence persist across different asthma severity and control status, underscoring the need for tailored medication management to improve asthma care.
UNASSIGNED: Data from the 2001-2020 National Health and Nutrition Examination Survey were used to estimate the weighted prevalence of polypharmacy. Joinpoint regression analysis was conducted to evaluate trends in polypharmacy. Trends were first evaluated overall and then stratified by asthma severity and asthma control. A multivariable logistic regression model was used to identify factors associated with polypharmacy.
UNASSIGNED: From 2001 to 2020, a stable trend in polypharmacy among U.S. adults with asthma was observed (average annual percent change [AAPC]=1.02, p=0.71). Trends across different asthma severity were stable (mild asthma: AAPC=2.93, p=0.20; moderate asthma: AAPC=-2.22, p=0.35; severe asthma: AAPC=0.45, p=0.82). Trends in adults with good asthma control and those with poor control stayed constant (good control: AAPC=0.82, p=0.68; poor control: AAPC=-1.22, p=0.82). Several factors, including older age, females, Non-Hispanic Black, health insurance coverage, family income, number of healthcare visits, former smokers, multi-morbidities, asthma severity, and asthma control, were associated with polypharmacy.
UNASSIGNED: Polypharmacy prevalence has remained constant among U.S. adults with asthma over the past two decades. Despite a stable overall trend, disparities in polypharmacy prevalence persist across different asthma severity and control status, underscoring the need for tailored medication management to improve asthma care.
摘要：
■本研究旨在评估美国成人哮喘患者的多药疗法患病率趋势。
■来自2001-2020年国家健康和营养检查调查的数据用于估计多重用药的加权患病率。进行Joinpoint回归分析以评估多重用药的趋势。首先对趋势进行总体评估，然后根据哮喘严重程度和哮喘控制进行分层。使用多变量逻辑回归模型来识别与多重用药相关的因素。
从2001年到2020年，观察到美国成人哮喘患者的多重用药趋势稳定（平均年变化百分比[AAPC]=1.02，P=0.71）。不同哮喘严重程度的趋势稳定（轻度哮喘：AAPC=2.93，P=0.20；中度哮喘：AAPC=-2.22，P=0.35；重度哮喘：AAPC=0.45，P=0.82）。哮喘控制良好的成年人和控制不良的成年人的趋势保持不变（控制良好：AAPC=0.82，P=0.68；控制不良：AAPC=-1.22，P=0.82）。几个因素,包括年龄较大,女性,非西班牙裔黑人,健康保险范围，家庭收入,医疗保健访问次数，前吸烟者,多发病,哮喘严重程度，和哮喘控制,与多重用药有关。
在过去的二十年中，美国成人哮喘患者的多重用药患病率保持不变。尽管总体趋势稳定，在不同的哮喘严重程度和控制状态下，多重用药的患病率存在差异，强调需要有针对性的药物管理来改善哮喘护理。
■来自2001-2020年国家健康和营养检查调查的数据用于估计多重用药的加权患病率。进行Joinpoint回归分析以评估多重用药的趋势。首先对趋势进行总体评估，然后根据哮喘严重程度和哮喘控制进行分层。使用多变量逻辑回归模型来识别与多重用药相关的因素。
从2001年到2020年，观察到美国成人哮喘患者的多重用药趋势稳定（平均年变化百分比[AAPC]=1.02，P=0.71）。不同哮喘严重程度的趋势稳定（轻度哮喘：AAPC=2.93，P=0.20；中度哮喘：AAPC=-2.22，P=0.35；重度哮喘：AAPC=0.45，P=0.82）。哮喘控制良好的成年人和控制不良的成年人的趋势保持不变（控制良好：AAPC=0.82，P=0.68；控制不良：AAPC=-1.22，P=0.82）。几个因素,包括年龄较大,女性,非西班牙裔黑人,健康保险范围，家庭收入,医疗保健访问次数，前吸烟者,多发病,哮喘严重程度，和哮喘控制,与多重用药有关。
在过去的二十年中，美国成人哮喘患者的多重用药患病率保持不变。尽管总体趋势稳定，在不同的哮喘严重程度和控制状态下，多重用药的患病率存在差异，强调需要有针对性的药物管理来改善哮喘护理。
